Company profile XNCR
After 38 days of this quarter the interest is at 143.0. Based on that we can calculate that during remaining 53 days it will total up to 342.0. Xencor expected interest is significantly lower compared to same quarter last year (-46.3%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 338 | 608 79.9% QoQ | 471 -22.5% QoQ | 345 -26.8% QoQ |
| 2020 | 424 25.4% YoY 22.9% QoQ | 348 -42.8% YoY -17.9% QoQ | 455 -3.4% YoY 30.7% QoQ | 263 -23.8% YoY -42.2% QoQ |
| 2021 | 306 -27.8% YoY 16.3% QoQ | 310 -10.9% YoY 1.3% QoQ | 348 -23.5% YoY 12.3% QoQ | 393 49.4% YoY 12.9% QoQ |
| 2022 | 376 22.9% YoY -4.3% QoQ | 458 47.7% YoY 21.8% QoQ | 351 0.9% YoY -23.4% QoQ | 378 -3.8% YoY 7.7% QoQ |
| 2023 | 637 69.4% YoY 68.5% QoQ | 483 5.5% YoY -24.2% QoQ | 560 59.5% YoY 15.9% QoQ | 363 -4.0% YoY -35.2% QoQ |
| 2024 | 143 -77.6% YoY -60.6% QoQ | - | - | - |
The average 5 years interest of Xencor was 32.15 per week. The last year interest of Xencor compared to the last 5 years has changed by 11.45%. The interest for Xencor is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -6.13%.
There is not enough data for Xencor biopharmaceutical company to provide analysis
There is not enough data for Xencor biopharmaceutical company to provide correlation calculation
There is not enough data for Xencor biopharmaceutical company to provide analysis
There is not enough data for Xencor clinical stage to provide analysis
There is not enough data for Xencor clinical stage to provide correlation calculation
There is not enough data for Xencor clinical stage to provide analysis
After 38 days of this quarter the interest is at 2.0. Based on that we can calculate that during remaining 53 days it will total up to 5.0. Sotrovimab expected interest is significantly lower compared to previous quarter (-50.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 4 | 4 0.0% QoQ | 2 -50.0% QoQ | 5 150.0% QoQ |
| 2020 | 3 -25.0% YoY -40.0% QoQ | 2 -50.0% YoY -33.3% QoQ | 3 50.0% YoY 50.0% QoQ | 5 0.0% YoY 66.7% QoQ |
| 2021 | 4 33.3% YoY -20.0% QoQ | 21 950.0% YoY 425.0% QoQ | 57 1800.0% YoY 171.4% QoQ | 184 3580.0% YoY 222.8% QoQ |
| 2022 | 571 14175.0% YoY 210.3% QoQ | 66 214.3% YoY -88.4% QoQ | 20 -64.9% YoY -69.7% QoQ | 11 -94.0% YoY -45.0% QoQ |
| 2023 | 8 -98.6% YoY -27.3% QoQ | 5 -92.4% YoY -37.5% QoQ | 6 -70.0% YoY 20.0% QoQ | 10 -9.1% YoY 66.7% QoQ |
| 2024 | 2 -75.0% YoY -80.0% QoQ | - | - | - |
The average 5 years interest of Sotrovimab was 3.82 per week. The last year interest of Sotrovimab compared to the last 5 years has changed by -86.39%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 67.74%.
After 38 days of this quarter the interest is at 162.0. Based on that we can calculate that during remaining 53 days it will total up to 388.0. Ultomiris expected interest is significantly higher compared to same quarter last year (+95.0%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 53 | 56 5.7% QoQ | 96 71.4% QoQ | 138 43.8% QoQ |
| 2020 | 119 124.5% YoY -13.8% QoQ | 124 121.4% YoY 4.2% QoQ | 129 34.4% YoY 4.0% QoQ | 114 -17.4% YoY -11.6% QoQ |
| 2021 | 97 -18.5% YoY -14.9% QoQ | 129 4.0% YoY 33.0% QoQ | 87 -32.6% YoY -32.6% QoQ | 74 -35.1% YoY -14.9% QoQ |
| 2022 | 106 9.3% YoY 43.2% QoQ | 198 53.5% YoY 86.8% QoQ | 235 170.1% YoY 18.7% QoQ | 176 137.8% YoY -25.1% QoQ |
| 2023 | 199 87.7% YoY 13.1% QoQ | 789 298.5% YoY 296.5% QoQ | 280 19.1% YoY -64.5% QoQ | 368 109.1% YoY 31.4% QoQ |
| 2024 | 162 -18.6% YoY -56.0% QoQ | - | - | - |
The average 5 years interest of Ultomiris was 14.34 per week. The last year interest of Ultomiris compared to the last 5 years has changed by 130.68%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 337.57%.
After 38 days of this quarter the interest is at 76.0. Based on that we can calculate that during remaining 53 days it will total up to 182.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 44 | 15 -65.9% QoQ | 36 140.0% QoQ | 21 -41.7% QoQ |
| 2020 | 37 -15.9% YoY 76.2% QoQ | 54 260.0% YoY 45.9% QoQ | 435 1108.3% YoY 705.6% QoQ | 255 1114.3% YoY -41.4% QoQ |
| 2021 | 327 783.8% YoY 28.2% QoQ | 387 616.7% YoY 18.3% QoQ | 310 -28.7% YoY -19.9% QoQ | 227 -11.0% YoY -26.8% QoQ |
| 2022 | 194 -40.7% YoY -14.5% QoQ | 256 -33.9% YoY 32.0% QoQ | 373 20.3% YoY 45.7% QoQ | 204 -10.1% YoY -45.3% QoQ |
| 2023 | 235 21.1% YoY 15.2% QoQ | 339 32.4% YoY 44.3% QoQ | 350 -6.2% YoY 3.2% QoQ | 166 -18.6% YoY -52.6% QoQ |
| 2024 | 76 -67.7% YoY -54.2% QoQ | - | - | - |
The average 5 years interest of Monjuvi was 16.7 per week. The last year interest of Monjuvi compared to the last 5 years has changed by 22.04%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 683.85%.
There is not enough data for Plamotamab trial to provide analysis
There is not enough data for Plamotamab trial to provide correlation calculation
There is not enough data for Plamotamab trial to provide analysis
There is not enough data for Vudalimab trial to provide analysis
There is not enough data for Vudalimab trial to provide correlation calculation
There is not enough data for Vudalimab trial to provide analysis
There is not enough data for XmAb306 trial to provide analysis
There is not enough data for XmAb306 trial to provide correlation calculation
There is not enough data for XmAb306 trial to provide analysis
There is not enough data for XmAb104 trial to provide analysis
There is not enough data for XmAb104 trial to provide correlation calculation
There is not enough data for XmAb104 trial to provide analysis
There is not enough data for XmAb564 trial to provide analysis
There is not enough data for XmAb564 trial to provide correlation calculation
There is not enough data for XmAb564 trial to provide analysis
There is not enough data for AMG 509 trial to provide analysis
There is not enough data for AMG 509 trial to provide correlation calculation
There is not enough data for AMG 509 trial to provide analysis
There is not enough data for XmAb819 trial to provide analysis
There is not enough data for XmAb819 trial to provide correlation calculation
There is not enough data for XmAb819 trial to provide analysis
There is not enough data for Novartis XmAb trial to provide analysis
There is not enough data for Novartis XmAb trial to provide correlation calculation
There is not enough data for Novartis XmAb trial to provide analysis
There is not enough data for XmAb541 trial to provide analysis
There is not enough data for XmAb541 trial to provide correlation calculation
There is not enough data for XmAb541 trial to provide analysis
There is not enough data for XmAb662 trial to provide analysis
There is not enough data for XmAb662 trial to provide correlation calculation
There is not enough data for XmAb662 trial to provide analysis
There is not enough data for VIR-3434 trial to provide analysis
There is not enough data for VIR-3434 trial to provide correlation calculation
There is not enough data for VIR-3434 trial to provide analysis
There is not enough data for VIR-2482 trial to provide analysis
There is not enough data for VIR-2482 trial to provide correlation calculation
There is not enough data for VIR-2482 trial to provide analysis
There is not enough data for AIMab7195 trial to provide analysis
There is not enough data for AIMab7195 trial to provide correlation calculation
There is not enough data for AIMab7195 trial to provide analysis
There is not enough data for Obexelimab trial to provide analysis
There is not enough data for Obexelimab trial to provide correlation calculation
There is not enough data for Obexelimab trial to provide analysis
There is not enough data for Xpro1595 trial to provide analysis
There is not enough data for Xpro1595 trial to provide correlation calculation
There is not enough data for Xpro1595 trial to provide analysis